A scalable platform to discover antimicrobials of ribosomal origin.
Richard S AyikpoeChengyou ShiAlexander J BattisteSara M EslamiSangeetha RameshMax A SimonIan R BothwellHyunji LeeAndrew J RiceHengqian RenQiqi TianLonnie A HarrisRaymond SarksianLingyang ZhuAutumn M FrerkTimothy W PrecordWilfred A van der DonkDouglas A MitchellHuimin ZhaoPublished in: Nature communications (2022)
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising source of new antimicrobials in the face of rising antibiotic resistance. Here, we report a scalable platform that combines high-throughput bioinformatics with automated biosynthetic gene cluster refactoring for rapid evaluation of uncharacterized gene clusters. As a proof of concept, 96 RiPP gene clusters that originate from diverse bacterial phyla involving 383 biosynthetic genes are refactored in a high-throughput manner using a biological foundry with a success rate of 86%. Heterologous expression of all successfully refactored gene clusters in Escherichia coli enables the discovery of 30 compounds covering six RiPP classes: lanthipeptides, lasso peptides, graspetides, glycocins, linear azol(in)e-containing peptides, and thioamitides. A subset of the discovered lanthipeptides exhibit antibiotic activity, with one class II lanthipeptide showing low µM activity against Klebsiella pneumoniae, an ESKAPE pathogen. Overall, this work provides a robust platform for rapidly discovering RiPPs.